The functioning liver mass

1991 ◽  
Vol 21 (1) ◽  
pp. 9-40 ◽  
Author(s):  
Gianpaolo Molino
Keyword(s):  
Liver Mass

Management of an Incidental Liver Mass

2010 ◽  
Vol 90 (4) ◽  
pp. 699-718 ◽  
Author(s):  
Cherif Boutros ◽  
Steven C. Katz ◽  
N. Joseph Espat
Keyword(s):  
Liver Mass

A 22-Year-Old Man with a Liver Mass and Markedly Elevated Serum Alpha Fetoprotein

1994 ◽  
Vol 14 (04) ◽  
pp. 395-403 ◽  
Author(s):  
Susan McCormick ◽  
Maria Sjogren ◽  
Zachary Goodman
Keyword(s):  
Elevated Serum ◽  
Alpha Fetoprotein ◽  
Liver Mass ◽  
Serum Alpha Fetoprotein

A young man with an atypical liver mass: Focal nodular hyperplasia

2021 ◽  
Vol 28 (3) ◽  
pp. 611
Author(s):  
Seyit Uyar ◽  
Ahmet Alparslan ◽  
Demet Aydin ◽  
Betul Erdogan ◽  
Gamze Kavas ◽  
...  
Keyword(s):  
Focal Nodular Hyperplasia ◽  
Liver Mass ◽  
Nodular Hyperplasia

Liver mass in a young male with Ollier disease

2021 ◽  
Author(s):  
Rajalakshmi Govalan ◽  
Maha Guindi ◽  
Ju Dong Yang
Keyword(s):  
Young Male ◽  
Liver Mass ◽  
Ollier Disease

Sulfonamide-Functionalized Polymeric Nanoparticles For Enhanced In Vivo Colorectal Cancer Therapy

2021 ◽  
Vol 18 ◽  
Author(s):  
Pedro Pires Goulart Guimarães ◽  
Celso Tarso Rodrigues Viana ◽  
Luciana Pereira ◽  
Savio Morato Lacerda Gontijo ◽  
Paula Peixoto Campos ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Polymeric Nanoparticles ◽  
Acquired Resistance ◽  
Lung Mass ◽  
Cancer Model ◽  
Liver Mass ◽  
Therapeutic Delivery ◽  
Promising Strategy ◽  
Common Cancer

Background: Colorectal cancer (CRC) is the third most common cancer in the world. 5-Fluorouracil (5-FU) is a conventional and most effective drug used in the clinic for the treatment of CRC. However, the clinical use of 5-FU is limited due to the acquired resistance and systemic toxicity, such as hepatotoxicity and gastrointesti-nal toxicity. Objective: Recent advances in nanomedicine are being exploited to develop nanoparticle platforms to overcome resistance and therapeutic delivery of active molecules. Here, we develop 5-FU loaded sulfadiazine-poly(lactide-co-glycolide) nanoparticles (SUL-PLGA NPs) to be applied in the colorectal cancer model. Methods: We assessed the in vivo efficacy of the SUL-PLGA NPs to enhance the antitumor effect of 5-FU. Results: In vivo treatment with 5-FU-SUL-PLGA NPs significantly reduced tumor growth in a colon cancer xen-ograft model compared to free 5-FU and 5-FU loaded non-targeted NPs. Treatment with 5-FU-SUL-PLGA NPs also increased blood vessel diameters within tumors, which could act in conjunction to enhance antitumor effi-cacy. In addition, 5-FU-SUL-PLGA NPs significantly reduced liver mass and lung mass, which are the most common metastasis sites of CRC, and decreased liver hepatotoxicity compared to free 5-FU drug and 5-FU loaded non-targeted NPs. Conclusion: Our findings suggest that the use of 5-FU-SUL-PLGA NPs is a promising strategy to enhance 5-FU efficacy against CRC.

Noncystic Liver Mass in the Pregnant Patient

1990 ◽  
Vol 83 (1) ◽  
pp. 51-53 ◽  
Author(s):  
DAVID A. MAGED ◽  
HERBERT J. KEATING
Keyword(s):  
Pregnant Patient ◽  
Liver Mass

scholarly journals Diurnal liver mass is associated with ribosome biogenesis

Oncotarget ◽  
2017 ◽  
Vol 8 (57) ◽  
pp. 96476-96477 ◽  
Author(s):  
Flore Sinturel ◽  
Frédéric Gachon
Keyword(s):  
Ribosome Biogenesis ◽  
Liver Mass

scholarly journals The molecular mechanism underlying the liver mass optimization rule

2008 ◽  
Author(s):  
R. Utoh ◽  
C. Tateno ◽  
K. Yoshizato
Keyword(s):  
Molecular Mechanism ◽  
Liver Mass ◽  
Optimization Rule
Sign in / Sign up

Export Citation Format

Share Document